Study of TA-TMA risk after stem cell transplant
Part of Blood & lymphatic clinical trials.
This study looks at how often a serious blood clotting problem (TA-TMA) happens after stem cell transplants. It follows two groups: people at high risk for TA-TMA and those with severe GVHD, and may test a drug called eculizumab for those who get TA-TMA.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You are getting a stem cell transplant from a donor at UAB
- You are either at high risk for a blood clotting complication (TA-TMA) or have severe GVHD
- You do not have another active cancer that needs treatment or is expected to shorten your life to less than a year
- If you can become pregnant, you agree to a pregnancy test before starting the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a two-step course of a drug called ATG (anti-thymocyte globulin) can help prevent a serious side effect called graft-versus-host disease (GVHD) after a donor stem cell transplant. It is for people with certain blood cancers who are receiving a reduced-intensity transplant.
This trial tests a two-step use of ATG (a drug that calms immune cells) to help prevent graft-versus-host disease (GVHD) in patients receiving a stem cell transplant from a donor. It may be an option for people with certain blood cancers or disorders who are getting a strong, marrow-clearing transplant.
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
This trial tests whether eculizumab can safely help people with a serious blood vessel complication called TA-TMA after a stem cell transplant. You may be eligible if you have high-risk features and haven't improved with initial care.
This study looks at people who have a blood clotting problem called TMA after a stem cell transplant from a donor. It gathers information from routine checkups to learn more about this condition.
This trial studies patients who have had a stem cell or solid organ transplant and may have a condition called TMA (small blood clots in vessels) or a viral infection. It aims to understand how certain immune system parts (complement and interferon) affect these conditions.
Hear when a new Transplant Complication trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.